The Toxin Head-to-Head ChallengeFor answers, Dermatology Times and Cosmetic Surgery Times developed an online survey for readers. The activity presented images from 6 patients who were photographed on the day of their injection and 30 days after treatment with either Xeomin® (incobotulinumtoxinA, Merz Pharmaceuticals) or Botox® (onabotulinumtoxinA, Allergan).
Neurotoxin pipeline advances, stay wary of counterfeitsAs the neurotoxin market is set for expansion, so expands the market of counterfeit products. One expert reviews the innovative options coming up through the pipeline and cautions colleagues about the risks associated with counterfeits.
Merz to acquire Ulthera for $600MMerz has entered a definitive merger agreement to acquire energy device maker Ulthera in a deal that could be valued at more than $600 million.
Reconstitution is key to optimizing neurotoxin results
Reconstitution is key to optimizing neurotoxin resultsSuboptimal reconstitution of botulinum toxin type A preparations can diminish the efficacy of neuromodulators for cosmetic use.
Epinephrine may prolong neuromodulator resultsMixing neuromodulators with epinephrine may give patients the longer-lasting results they seek, according to an expert at Cosmetic Surgery Forum. This combination, however, may not prove beneficial for everyone.
Navigating neurotoxins’ differencesWe now have three neurotoxins in our marketplace. Do you feel that these neurotoxins differ, and if so, how? An expert panel addresses the topic at the 2013 Vegas Cosmetic Surgery and Aesthetic Dermatology meeting.
Merz to acquire NeocutisMerz Pharma Group has entered into an agreement with Neocutis to acquire its cosmetic, prescription and over-the-counter skincare products.
Valeant outbids Merz for ObagiAfter Valeant Pharmaceuticals made a push to buy Obagi Medical Products for about $344 million in late March, Merz Pharma Group stepped up with an offer of about $384 million, but has since dropped its bid for the aesthetic skincare manufacturer, according to reports.
Xeomin cleared to re-enter U.S. marketHaving reached the end of a 10-month injunction barring it from selling its botulinum toxin product in the U.S., Merz is once again launching Xeomin for the treatment of glabellar lines.